Novel and conventional receptors for ghrelin, desacyl-ghrelin, and pharmacologically related compounds

Pharmacological Reviews

Volumn 66, Issue 4, 2014, Pages 984-1001

  Callaghan, Brid ^a   Furness, John B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DESACYL GHRELIN; GHRELIN RECEPTOR; GROWTH HORMONE SECRETAGOGUE RECEPTOR 1B; HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; LIGAND; NITRIC OXIDE; UNCLASSIFIED DRUG; GHRELIN; GHRELIN, DES-N-OCTANOYL;

ADIPOSE TISSUE; APPETITE; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CORONARY ARTERY CONSTRICTION; ENDOTHELIUM CELL; GLUCOSE TOLERANCE; HEART PROTECTION; HUMAN; INOTROPISM; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID STORAGE; MYOBLAST; OSTEOBLAST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; SKELETAL MUSCLE; TUMOR CELL; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; METABOLISM;

ANIMALS; GHRELIN; HUMANS; RECEPTORS, GHRELIN;

EID: 84919768782     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.113.008433     Document Type: Article

References (205)

1. Adams EF, Petersen B, Lei T, Buchfelder M, and Fahlbusch R (1995) The growth hormone secretagogue, L-692,429, induces phosphatidylinositol hydrolysis and hormone secretion by human pituitary tumors. Biochem Biophys Res Commun 208: 555-561.
2. Alexander SPH, Mathie A, and Peters JA (2011) Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl 1):S1-S324.
3. Andrews S, Stephens LR, and Hawkins PT (2007) PI3K class IB pathway. Sci STKE 407:cm2 DOI: 10.1126/stke.4072007cm2.
4. Ariyasu H, Takaya K, Iwakura H, Hosoda H, Akamizu T, Arai Y, Kangawa K, and Nakao K (2005) Transgenic mice overexpressing des-acyl ghrelin show small phenotype. Endocrinology 146:355-364.
5. Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, and Kasuga M (2005) Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54:18-24.
6. Atcha Z, Chen W-S, Ong AB, Wong F-K, Neo A, Browne ER, Witherington J, and Pemberton DJ (2009) Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology (Berl) 206:415-427.
7. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, and Broglio F, et al. (2002) Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/ AKT. J Cell Biol 159:1029-1037.
8. Baragli A, Ghè C, Arnoletti E, Granata R, Ghigo E, and Muccioli G (2011) Acylated and unacylated ghrelin attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase g and phosphodiesterase 3B. Biochim Biophys Acta 1811:386-396.
9. Barakat KJ, Cheng K, Chan WW-S, Butler BS, Jacks TM, Schleim KD, Hora DF Jr, Hickey GJ, Smith RG, and Patchett AA, et al. (1998) Synthesis and biological activities of phenyl piperazine-based peptidomimetic growth hormone secretagogues. Bioorg Med Chem Lett 8:1431-1436.
10. Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghé C, Deghenghi R, Ghigo E, and Muccioli G (2003) Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 476:87-95.
11. Bednarek MA, Feighner SD, Pong S-S, McKee KK, Hreniuk DL, Silva MV, Warren VA, Howard AD, Van Der Ploeg LHY, and Heck JV (2000) Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 43:4370-4376.
12. Beiras-Fernandez A, Kreth S, Weis F, Ledderose C, Pöttinger T, Dieguez C, Beiras A, and Reichart B (2010) Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. Peptides 31:2222-2228.
13. Bennett KA, Langmead CJ, Wise A, and Milligan G (2009) Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor. Mol Pharmacol 76:802-811.
14. Benso A, St-Pierre DH, Prodam F, Gramaglia E, Granata R, van der Lely AJ, Ghigo E, and Broglio F (2012) Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. Eur J Endocrinol 166:911-916.
15. Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, and Jackson VM, et al. (2014) Discovery of PF-5190457, a potent, selective, and orally bioavailable ghrelin receptor inverse agonist clinical candidate. ACS Med Chem Lett 5:474-479.
16. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, and Lamontagne D, et al. (2002) CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 90:844-849.
17. Bowers CY, Momany FA, Reynolds GA, and Hong A (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537-1545.
18. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, and Ghigo E (2001) Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 86:5083-5086.
19. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, Abribat T, Van Der Lely AJ, and Ghigo E (2004) Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 89:3062-3065.
20. Bulgarelli I, Tamiazzo L, Bresciani E, Rapetti D, Caporali S, Lattuada D, Locatelli V, and Torsello A (2009) Desacyl-ghrelin and synthetic GH-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by b-amyloid fibrils. J Neurosci Res 87:2718-2727.
21. Callaghan B, Hunne B, Hirayama H, Sartor DM, Nguyen TV, Abogadie FC, Ferens D, McIntyre P, Ban K, and Baell J, et al. (2012) Sites of action of ghrelin receptor ligands in cardiovascular control. Am J Physiol Heart Circ Physiol 303: H1011-H1021.
22. Callaghan B, Kosari S, Pustovit RV, Sartor DM, Ferens D, Ban K, Baell J, Nguyen TV, Rivera LR, and Brock JA, et al. (2014) Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol 171:1275-1286.
23. Camiña JP (2006) Cell biology of the ghrelin receptor. J Neuroendocrinol 18:65-76.
24. Caminos JE, Gualillo O, Lago F, Otero M, Blanco M, Gallego R, Garcia-Caballero T, Goldring MB, Casanueva FF, and Gomez-Reino JJ, et al. (2005) The endogenous growth hormone secretagogue (ghrelin) is synthesized and secreted by chondrocytes. Endocrinology 146:1285-1292.
25. Cannon WB and Washburn AL (1912) An explanation of hunger. Am J Physiol 29: 441-454.
26. Carlson AJ (1913) Contributions to the physiology of the stomach-II The relation between the contractions of the empty stomach and the sensation of hunger. Am J Physiol 31:175-192.
27. Carpino PA, Lefker BA, Toler SM, Pan LC, Hadcock JR, Murray MC, Cook ER, DiBrino JN, DeNinno SL, and Chidsey-Frink KL, et al. (2002) Discovery and biological characterization of capromorelin analogues with extended half-lives. Bioorg Med Chem Lett 12:3279-3282.
28. Cassoni P, Ghé C, Marrocco T, Tarabra E, Allia E, Catapano F, Deghenghi R, Ghigo E, Papotti M, and Muccioli G (2004) Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol 150:173-184.
29. Cassoni P, Papotti M, Ghè C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, and Muccioli G (2001) Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 86:1738-1745.
30. Chan C-B and Cheng CHK (2004) Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Acanthopagrus schlegeli. Mol Cell Endocrinol 214: 81-95.
31. Chang CH, Rickes EL, McGuire L, Frazier E, Chen H, Barakat K, Nargund R, Patchett A, Smith RG, and Hickey GJ (1996) Growth hormone (GH) and insulinlike growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine. Endocrinology 137:4851-4856.
32. Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, Weintraub NL, and Tang C (2004a) Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 43:165-170.
33. Chang L, Zhao J, Li GZ, Geng B, Pan CS, Qi YF, and Tang CS (2004b) Ghrelin protects myocardium from isoproterenol-induced injury in rats. Acta Pharmacol Sin 25:1131-1137.
34. Chen C-Y, Asakawa A, Fujimiya M, Lee S-D, and Inui A (2009) Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 61:430-481.
35. Cheng K, Chan WW-S, Barreto A Jr, Convey EM, and Smith RG (1989) The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 124:2791-2798.
36. Choi K, Roh S-G, Hong Y-H, Shrestha YB, Hishikawa D, Chen C, Kojima M, Kangawa K, and Sasaki S (2003) The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. Endocrinology 144:754-759.
37. Chollet C, Bergmann R, Pietzsch J, and Beck-Sickinger AG (2012) Design, evaluation, and comparison of ghrelin receptor agonists and inverse agonists as suitable radiotracers for PET imaging. Bioconjug Chem 23:771-784.
38. Chollet C, Meyer K, and Beck-Sickinger AG (2009) Ghrelin-a novel generation of anti-obesity drug: design, pharmacomodulation and biological activity of ghrelin analogues. J Pept Sci 15:711-730.
39. Chopin LK, Seim I, Walpole CM, and Herington AC (2012) The ghrelin axis-does it have an appetite for cancer progression? Endocr Rev 33:849-891.
40. Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, and Gertz BJ, et al. (2001) Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther 70:91-98.
41. Córdoba-Chacón J, Gahete MD, Pozo-Salas AI, Martínez-Fuentes AJ, de Lecea L, Gracia-Navarro F, Kineman RD, Castaño JP, and Luque RM (2011) Cortistatin is not a somatostatin analogue but stimulates prolactin release and inhibits GH and ACTH in a gender-dependent fashion: potential role of ghrelin. Endocrinology 152: 4800-4812.
42. Costa JL, Naot D, Lin J-M, Watson M, Callon KE, Reid IR, Grey AB, and Cornish J (2011) Ghrelin is an osteoblast mitogen and increases osteoclastic bone resorption in vitro. Int J Pept 2011:605193 DOI: 10.1155/2011/605193.
43. Costantini VJA, Vicentini E, Sabbatini FM, Valerio E, Lepore S, Tessari M, Sartori M, Michielin F, Melotto S, and Bifone A, et al. (2011) GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 94:158-168.
44. Crujeiras AB, Goyenechea E, Abete I, Lage M, Carreira MC, Martínez JA, and Casanueva FF (2010) Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab 95:5037-5044.
45. Damian M, Marie J, Leyris J-P, Fehrentz J-A, Verdié P, Martinez J, Banères J-L, and Mary S (2012) High constitutive activity is an intrinsic feature of ghrelin receptor protein: a study with a functional monomeric GHS-R1a receptor reconstituted in lipid discs. J Biol Chem 287:3630-3641.
46. Davies JS, Kotokorpi P, Eccles SR, Barnes SK, Tokarczuk PF, Allen SK, Whitworth HS, Guschina IA, Evans BAJ, and Mode A, et al. (2009) Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol 23:914-924.
47. Deboer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G, Mitch WE, Taylor JE, Halem HA, and Dong JZ, et al. (2008) Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149:827-835.
48. Deghenghi R, Papotti M, Ghigo E, and Muccioli G (2001) Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J Endocrinol Invest 24:RC1-RC3.
49. Delhanty PJD, Huisman M, Baldeon-Rojas LY, van den Berge I, Grefhorst A, Abribat T, Leenen PJM, Themmen APN, and van der Lely A-J (2013) Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucose homeostasis. FASEB J 27:1690-1700.
50. Delhanty PJD, Sun Y, Visser JA, van Kerkwijk A, Huisman M, van Ijcken WFJ, Swagemakers S, Smith RG, Themmen APN, and van der Lely AJ (2010) Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS ONE 5:e11749.
51. Delhanty PJD, van der Eerden BCJ, van der Velde M, Gauna C, Pols HAP, Jahr H, Chiba H, van der Lely AJ, and van Leeuwen JPTM (2006) Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol 188:37-47.
52. Dello Russo C, Lisi L, Navarra P, and Tringali G (2009) Diverging effects of cortistatin and somatostatin on the production and release of prostanoids from rat cortical microglia and astrocytes. J Neuroimmunol 213:78-83.
53. Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, and Ong H (2004) Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J 382:417-424.
54. Dezaki K, Kakei M, and Yada T (2007) Ghrelin uses Galphai2 and activates voltage-dependent K+ channels to attenuate glucose-induced Ca2+ signaling and insulin release in islet b-cells: novel signal transduction of ghrelin. Diabetes 56:2319-2327.
55. Dieci E, Casati L, Pagani F, Celotti F, and Sibilia V (2014) Acylated and unacylated ghrelin protect MC3T3-E1 cells against tert-butyl hydroperoxide-induced oxidative injury: pharmacological characterization of ghrelin receptor and possible epigenetic involvement. Amino Acids 46:1715-1725.
56. Els S, Schild E, Petersen PS, Kilian T-M, Mokrosinski J, Frimurer TM, Chollet C, Schwartz TW, Holst B, and Beck-Sickinger AG (2012) An aromatic region to induce a switch between agonism and inverse agonism at the ghrelin receptor. J Med Chem 55:7437-7449.
57. Esler WP, Rudolph J, Claus TH, Tang W, Barucci N, Brown S-E, Bullock W, Daly M, Decarr L, and Li Y, et al. (2007) Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148:5175-5185.
58. Favaro E, Granata R, Miceli I, Baragli A, Settanni F, Cavallo Perin P, Ghigo E, Camussi G, and Zanone MM (2012) The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia 55:1058-1070.
59. Feighner SD, Howard AD, Prendergast K, Palyha OC, Hreniuk DL, Nargund R, Underwood D, Tata JR, Dean DC, and Tan CP, et al. (1998) Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol 12:137-145.
60. Filigheddu N, Gnocchi VF, Coscia M, Cappelli M, Porporato PE, Taulli R, Traini S, Baldanzi G, Chianale F, and Cutrupi S, et al. (2007) Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell 18: 986-994.
61. Frascarelli S, Ghelardoni S, Ronca-Testoni S, and Zucchi R (2003) Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 98:401-405.
62. Fraser GL, Hoveyda HR, and Tannenbaum GS (2008) Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. Endocrinology 149:6280-6288.
63. Gahete MD, Córdoba-Chacón J, Hergueta-Redondo M, Martínez-Fuentes AJ, Kineman RD, Moreno-Bueno G, Luque RM, and Castaño JP (2011) A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance. PLoS ONE 6:e23302.
64. Garcia JM, Friend J, and Allen S (2013) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21:129-137.
65. Garcia JM and Polvino WJ (2007) Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12:594-600.
66. Garcia JM and Polvino WJ (2009) Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 19:267-273.
67. Garin MC, Burns CM, Kaul S, and Cappola AR (2013) Clinical review: The human experience with ghrelin administration. J Clin Endocrinol Metab 98:1826-1837.
68. Gauna C, Delhanty PJD, Hofland LJ, Janssen JAMJL, Broglio F, Ross RJM, Ghigo E, and van der Lely AJ (2005) Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 90: 1055-1060.
69. Gauna C, Kiewiet RM, Janssen JAMJL, van de Zande B, Delhanty PJD, Ghigo E, Hofland LJ, Themmen APN, and van der Lely AJ (2007a) Unacylated ghrelin acts as potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab 293:E697-E704.
70. Gauna C, van de Zande B, van Kerkwijk A, Themmen APN, van der Lely AJ, and Delhanty PJD (2007b) Unacylated ghrelin is not a functional antagonist but a full agonist of the type 1a growth hormone secretagogue receptor (GHS-R). Mol Cell Endocrinol 274:30-34.
71. Gershon E and Vale WW (2014) CRF type 2 receptors mediate the metabolic effects of ghrelin in C2C12 cells. Obesity (Silver Spring) 22:380-389.
72. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, and Camanni F (1994) Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 78:693-698.
73. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, and Korbonits M (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988-2991.
74. Gozé C, Bergé G, M'Kadmi C, Floquet N, Gagne D, Galleyrand J-C, Fehrentz J-A, and Martinez J (2010) Involvement of tryptophan W276 and of two surrounding amino acid residues in the high constitutive activity of the ghrelin receptor GHS-R1a. Eur J Pharmacol 643:153-161.
75. Granata R, Settanni F, Biancone L, Trovato L, Nano R, Bertuzzi F, Destefanis S, Annunziata M, Martinetti M, and Catapano F, et al. (2007) Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic b-cells and human islets: involvement of 39,59-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/ Akt signaling. Endocrinology 148:512-529.
76. Granata R, Settanni F, Julien M, Nano R, Togliatto G, Trombetta A, Gallo D, Piemonti L, Brizzi MF, and Abribat T, et al. (2012) Des-acyl ghrelin fragments and analogues promote survival of pancreatic b-cells and human pancreatic islets and prevent diabetes in streptozotocin-treated rats. J Med Chem 55:2585-2596.
77. Grönberg M, Fjällskog M-L, Jirström K, and Janson ET (2011) Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. Acta Oncol (Madr) 51:386-393.
78. Grönberg M, Tsolakis AV, Magnusson L, Janson ET, and Saras J (2008) Distribution of obestatin and ghrelin in human tissues: immunoreactive cells in the gastrointestinal tract, pancreas, and mammary glands. J Histochem Cytochem 56:793-801.
79. Grossini E, Molinari C, Mary DASG, Ghigo E, Bona G, and Vacca G (2007) Intracoronary ghrelin infusion decreases coronary blood flow in anesthetized pigs. Endocrinology 148:806-812.
80. Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R, Locatelli V, Torsello A, Ghé C, and Catapano F, et al. (2003) New active series of growth hormone secretagogues. J Med Chem 46:1191-1203.
81. Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, Witcher DR, Luo S, Onyia JE, and Hale JE (2008) Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 105:6320-6325.
82. Halem HA, Taylor JE, Dong JZ, Shen Y, Datta R, Abizaid A, Diano S, Horvath TL, and Culler MD (2005) A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology 81:339-349.
83. Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, and Ankersen M (1999) Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol 141:180-189.
84. Hirayama H, Shiina T, Shima T, Kuramoto H, Takewaki T, B Furness J, and Shimizu Y (2010) Contrasting effects of ghrelin and des-acyl ghrelin on the lumbo-sacral defecation center and regulation of colorectal motility in rats. Neurogastroenterol Motil 22:1124-1131.
85. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, and Schwartz TW (2003) High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol Endocrinol 17:2201-2210.
86. Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, and Schwartz TW (2009) Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol Pharmacol 75:44-59.
87. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, and Schwartz TW (2004) Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem 279:53806-53817.
88. Holst B, Lang M, Brandt E, Bach A, Howard A, Frimurer TM, Beck-Sickinger A, and Schwartz TW (2006) Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol Pharmacol 70: 936-946.
89. Holst B, Mokrosinski J, Lang M, Brandt E, Nygaard R, Frimurer TM, Beck-Sickinger AG, and Schwartz TW (2007) Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem 282:15799-15811.
90. Hoveyda HR, Marsault E, Gagnon R, Mathieu AP, Vézina M, Landry A, Wang Z, Benakli K, Beaubien S, and Saint-Louis C, et al. (2011) Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. J Med Chem 54:8305-8320.
91. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, and Anderson J, et al. (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977.
92. Iantorno M, Chen H, Kim JA, Tesauro M, Lauro D, Cardillo C, and Quon MJ (2007) Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 292:E756-E764.
93. Iglesias MJ, Piñeiro R, Blanco M, Gallego R, Diéguez C, Gualillo O, González-Juanatey JR, and Lago F (2004) Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 62:481-488.
94. Inhoff T, Mönnikes H, Noetzel S, Stengel A, Goebel M, Dinh QT, Riedl A, Bannert N, Wisser A-S, and Wiedenmann B, et al. (2008) Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats. Peptides 29:2159-2168.
95. Inoue Y, Nakahara K, Maruyama K, Suzuki Y, Hayashi Y, Kangawa K, and Murakami N (2013) Central and peripheral des-acyl ghrelin regulates body temperature in rats. Biochem Biophys Res Commun 430:278-283.
96. Jeffery PL, Herington AC, and Chopin LK (2002) Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol 172:R7-R11.
97. Jeffery PL, Murray RE, Yeh AH, McNamara JF, Duncan RP, Francis GD, Herington AC, and Chopin LK (2005) Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocr Relat Cancer 12:839-850.
98. Jiang H, Betancourt L, and Smith RG (2006) Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol 20:1772-1785.
99. Julien M, Kay RG, Delhanty PJD, Allas S, Granata R, Barton C, Constable S, Ghigo E, van der Lely AJ, and Abribat T (2012) In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analogues. Eur J Pharm Sci 47: 625-635.
100. Katugampola SD, Pallikaros Z, and Davenport AP (2001) [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol 134:143-149.
101. Kern A, Albarran-Zeckler R, Walsh HE, and Smith RG (2012) Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73:317-332.
102. Kiewiet RM, van Aken MO, van der Weerd K, Uitterlinden P, Themmen APN, Hofland LJ, de Rijke YB, Delhanty PJD, Ghigo E, and Abribat T, et al. (2009) Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. Eur J Endocrinol 161:567-573.
103. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, Han BH, Kim MS, Shin CS, and Kim SY (2005) Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone 37:359-369.
104. Kohno D, Gao H-Z, Muroya S, Kikuyama S, and Yada T (2003) Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 52:948-956.
105. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, and Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
106. Kojima M and Kangawa K (2005) Ghrelin: structure and function. Physiol Rev 85: 495-522.
107. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, and Grossman AB (2001) The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 86:881-887.
108. Kos K, Harte AL, O'Hare PJ, Kumar S, and McTernan PG (2009) Ghrelin and the differential regulation of des-acyl (DSG) and oct-anoyl ghrelin (OTG) in human adipose tissue (AT). Clin Endocrinol (Oxf) 70:383-389.
109. Kung DW, Coffey SB, Jones RM, Cabral S, Jiao W, Fichtner M, Carpino PA, Rose CR, Hank RF, and Lopaze MG, et al. (2012) Identification of spirocyclic piperidineazetidine inverse agonists of the ghrelin receptor. Bioorg Med Chem Lett 22: 4281-4287.
110. Lambert E, Lambert G, Ika-Sari C, Dawood T, Lee K, Chopra R, Straznicky N, Eikelis N, Drew S, and Tilbrook A, et al. (2011) Ghrelin modulates sympathetic nervous system activity and stress response in lean and overweight men. Hypertension 58: 43-50.
111. Lanfranco F, Baldi M, Cassoni P, Bosco M, Ghé C, and Muccioli G (2008) Ghrelin and prostate cancer. Vitam Horm 77:301-324.
112. Lasseter KC, Shaughnessy L, Cummings D, Pezzullo JC, Wargin W, Gagnon R, Oliva J, and Kosutic G (2008) Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 48:193-202.
113. Lear PV, Iglesias MJ, Feijóo-Bandín S, Rodríguez-Penas D, Mosquera-Leal A, García-Rúa V, Gualillo O, Ghè C, Arnoletti E, and Muccioli G, et al. (2010) Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes. Endocrinology 151:3286-3298.
114. Leontiou CA, Franchi G, and Korbonits M (2007) Ghrelin in neuroendocrine organs and tumours. Pituitary 10:213-225.
115. Lim CT, Kola B, Feltrin D, Perez-Tilve D, Tschöp MH, Grossman AB, and Korbonits M (2013) Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. Mol Cell Endocrinol 365:303-308.
116. Lin L, Saha PK, Ma X, Henshaw IO, Shao L, Chang BHJ, Buras ED, Tong Q, Chan L, and McGuinness OP, et al. (2011) Ablation of ghrelin receptor reduces adiposity and improves insulin sensitivity during aging by regulating fat metabolism in white and brown adipose tissues. Aging Cell 10:996-1010.
117. Liu G, Fortin J-P, Beinborn M, and Kopin AS (2007) Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities. J Pharmacol Exp Ther 322:1036-1043.
118. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Müller EE, and Berti F (1999) Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 140:4024-4031.
119. Ma X, Lin L, Yue J, Pradhan G, Qin G, Minze LJ, Wu H, Sheikh-Hamad D, Smith CW, and Sun Y (2013) Ghrelin receptor regulates HFCS-induced adipose inflammation and insulin resistance. Nutr Diabetes 3:e99.
120. MacLean CM, Casanova A-T, Baselgia-Jeker L, Neave N, Larsen F, Skillern L, Drewe J, and Beglinger C (2009) Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. J Clin Pharmacol 49:553-559.
121. Mary S, Damian M, Louet M, Floquet N, Fehrentz J-A, Marie J, Martinez J, and Banères J-L (2012) Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc Natl Acad Sci USA 109:8304-8309.
122. Mary S, Fehrentz J-A, Damian M, Gaibelet G, Orcel H, Verdié P, Mouillac B, Martinez J, Marie J, and Banères J-L (2013) Heterodimerization with Its splice variant blocks the ghrelin receptor 1a in a non-signaling conformation: a study with a purified heterodimer assembled into lipid discs. J Biol Chem 288:24656-24665.
123. Matsumoto M, Hosoda H, Kitajima Y, Morozumi N, Minamitake Y, Tanaka S, Matsuo H, Kojima M, Hayashi Y, and Kangawa K (2001) Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun 287:142-146.
124. McClure KF, Jackson M, Cameron KO, Kung DW, Perry DA, Orr STM, Zhang Y, Kohrt J, Tu M, and Gao H, et al. (2013) Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor. Bioorg Med Chem Lett 23: 5410-5414.
125. McGirr R, McFarland MS, McTavish J, Luyt LG, and Dhanvantari S (2011) Design and characterization of a fluorescent ghrelin analog for imaging the growth hormone secretagogue receptor 1a. Regul Pept 172:69-76.
126. McKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS, Smith RG, Van der Ploeg LHT, and Howard AD (1997) Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol 11:415-423.
127. Mear Y, Enjalbert A, and Thirion S (2013) GHS-R1a constitutive activity and its physiological relevance. Front Neurosci 7:1-7.
128. Miegueu P, St Pierre D, Broglio F, and Cianflone K (2011) Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. J Cell Biochem 112:704-714.
129. Mokrosinski J, Frimurer TM, Sivertsen B, Schwartz TW, and Holst B (2012) Modulation of constitutive activity and signaling bias of the ghrelin receptor by conformational constraint in the second extracellular loop. J Biol Chem 287:33488-33502.
130. Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML, Ivorra C, Dominguez M, Conde L, and Millán C, et al. (2010) Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 51:974-985.
131. Moulin A, Demange L, Ryan J, Mousseaux D, Sanchez P, Bergé G, Gagne D, Perrissoud D, Locatelli V, and Torsello A, et al. (2008) New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem 51:689-693.
132. Muccioli G, Baragli A, Granata R, Papotti M, and Ghigo E (2007) Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology 86: 147-164.
133. Muccioli G, Papotti M, Locatelli V, Ghigo E, and Deghenghi R (2001) Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 24:RC7-RC9.
134. Muccioli G, Pons N, Ghè C, Catapano F, Granata R, and Ghigo E (2004) Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 498:27-35.
135. Murata M, Okimura Y, Iida K, Matsumoto M, Sowa H, Kaji H, Kojima M, Kangawa K, and Chihara K (2002) Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 277:5667-5674.
136. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, and Gertz BJ; MK-677/Alendronate Study Group (2001) Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 86:1116-1125.
137. Nagamine J, Nagata R, Seki H, Nomura-Akimaru N, Ueki Y, Kumagai K, Taiji M, and Noguchi H (2001) Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686. J Endocrinol 171:481-489.
138. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, and Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194-198.
139. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, and Thorner MO (2008) Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 149:601-611.
140. Neary NM, Druce MR, Small CJ, and Bloom SR (2006) Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. Gut 55:135.
141. Nikolopoulos D, Theocharis S, and Kouraklis G (2010) Ghrelin's role on gastrointestinal tract cancer. Surg Oncol 19:e2-e10.
142. Pan LC, Carpino PA, Lefker BA, Ragan JA, Toler SM, Pettersen JC, Nettleton DO, Ng O, Pirie CM, and Chidsey-Frink K, et al. (2001) Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine growth hormone secretagogue. Endocrine 14:121-132.
143. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, Morisset S, Nivot S, Vie-Luton M-P, Grouselle D, and de Kerdanet M, et al. (2006) Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 116:760-768.
144. Park S, Jiang H, Zhang H, and Smith RG (2012) Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release. Proc Natl Acad Sci USA 109:19003-19008.
145. Patterson M, Murphy KG, le Roux CW, Ghatei MA, and Bloom SR (2005) Characterization of ghrelin-like immunoreactivity in human plasma. J Clin Endocrinol Metab 90:2205-2211.
146. Paul BJ, Littler BJ, Jos F, and Vogt PF (2006) A practical synthesis of the pseudotripeptide RC-1291. Org Process Res Dev 10:339-345.
147. Pei XM, Yung BY, Yip SP, Ying M, Benzie IF, and Siu PM (2014) Desacyl ghrelin prevents doxorubicin-induced myocardial fibrosis and apoptosis via the GHSR-independent pathway. Am J Physiol Endocrinol Metab 306:E311-E323.
148. Pellegrino S, Ruscica M, Magni P, Vistoli G, and Gelmi ML (2013) Antiproliferative activity on human prostate carcinoma cell lines of new peptidomimetics containing the spiroazepinoindolinone scaffold. Bioorg Med Chem 21:5470-5479.
149. Pemberton CJ, Tokola H, Bagi Z, Koller A, Pöntinen J, Ola A, Vuolteenaho O, Szokodi I, and Ruskoaho H (2004) Ghrelin induces vasoconstriction in the rat coronary vasculature without altering cardiac peptide secretion. Am J Physiol Heart Circ Physiol 287:H1522-H1529.
150. Perdonà E, Faggioni F, Buson A, Sabbatini FM, Corti C, and Corsi M (2011) Pharmacological characterization of the ghrelin receptor antagonist, GSK1614343 in rat RC-4B/C cells natively expressing GHS type 1a receptors. Eur J Pharmacol 650: 178-183.
151. Petersen PS, Woldbye DPD, Madsen AN, Egerod KL, Jin C, Lang M, Rasmussen M, Beck-Sickinger AG, and Holst B (2009) In vivo characterization of high Basal signaling from the ghrelin receptor. Endocrinology 150:4920-4930.
152. Porporato PE, Filigheddu N, Reano S, Ferrara M, Angelino E, Gnocchi VF, Prodam F, Ronchi G, Fagoonee S, and Fornaro M, et al. (2013) Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 123:611-622.
153. Prodam F, Benso A, Gramaglia E, Lucatello B, Riganti F, van der Lely AJ, Deghenghi R, Muccioli G, Ghigo E, and Broglio F (2008) Cortistatin-8, a synthetic cortistatinderived ghrelin receptor ligand, does not modify the endocrine responses to acylated ghrelin or hexarelin in humans. Neuropeptides 42:89-93.
154. Qi Y, Longo KA, Giuliana DJ, Gagne S, McDonagh T, Govek E, Nolan A, Zou C, Morgan K, and Hixon J, et al. (2011) Characterization of the insulin sensitivity of ghrelin receptor KO mice using glycemic clamps. BMC Physiol 11:1-8.
155. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, and Andersen PH (1998) Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 139:552-561.
156. Reano S, Graziani A, and Filigheddu N (2014) Acylated and unacylated ghrelin administration to blunt muscle wasting. Curr Opin Clin Nutr Metab Care 17: 236-240.
157. Rediger A, Piechowski CL, Yi C-X, Tarnow P, Strotmann R, Grüters A, Krude H, Schöneberg T, Tschöp MH, and Kleinau G, et al. (2011) Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors. J Biol Chem 286:39623-39631.
158. Rodríguez A, Gómez-Ambrosi J, Catalán V, Gil MJ, Becerril S, Sáinz N, Silva C, Salvador J, Colina I, and Frühbeck G (2009) Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 33: 541-552.
159. Sabbatini FM, Di Fabio R, Corsi M, Cavanni P, Bromidge SM, St-Denis Y, D'Adamo L, Contini S, Rinaldi M, and Guery S, et al. (2010) Discovery process and characterization of novel carbohydrazide derivatives as potent and selective GHSR1a antagonists. ChemMedChem 5:1450-1455.
160. Salomé N, Haage D, Perrissoud D, Moulin A, Demange L, Egecioglu E, Fehrentz J-A, Martinez J, and Dickson SL (2009) Anorexigenic and electrophysiological actions of novel ghrelin receptor (GHS-R1A) antagonists in rats. Eur J Pharmacol 612: 167-173.
161. Schellekens H, van Oeffelen WEPA, Dinan TG, and Cryan JF (2013) Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling. J Biol Chem 288:181-191.
162. Schwartz TW (1994) Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5:434-444.
163. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, and Elling CE (2006) Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu Rev Pharmacol Toxicol 46:481-519.
164. Seim I, Josh P, Cunningham P, Herington A, and Chopin L (2011) Ghrelin axis genes, peptides and receptors: recent findings and future challenges. Mol Cell Endocrinol 340:3-9.
165. Shaw M, Pediconi C, McVey D, Mondou E, Quinn J, Chamblin B, and Rousseau F (2013) Safety and efficacy of ulimorelin administered postoperatively to accelerate recovery of gastrointestinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials. Dis Colon Rectum 56:888-897.
166. Sheriff S, Kadeer N, Joshi R, Friend LA, James JH, and Balasubramaniam A (2012) Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol Cell Endocrinol 351:286-295.
167. Shimada T, Furuta H, Doi A, Ariyasu H, Kawashima H, Wakasaki H, Nishi M, Sasaki H, and Akamizu T (2014) Des-acyl ghrelin protects microvascular endothelial cells from oxidative stress-induced apoptosis through sirtuin 1 signaling pathway. Metabolism 63:469-474.
168. Shimizu Y, Nagaya N, Teranishi Y, Imazu M, Yamamoto H, Shokawa T, Kangawa K, Kohno N, and Yoshizumi M (2003) Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 310:830-835.
169. Shin A, Camilleri M, Busciglio I, Burton D, Stoner E, Noonan P, Gottesdiener K, Smith SA, Vella A, and Zinsmeister AR (2013) Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 36:41-48.
170. Sivertsen B, Holliday N, Madsen AN, and Holst B (2013) Functionally biased signalling properties of 7TM receptors-opportunities for drug development for the ghrelin receptor. Br J Pharmacol 170:1349-1362.
171. Smith RG (2005) Development of growth hormone secretagogues. Endocr Rev 26: 346-360.
172. Soares J-B and Leite-Moreira AF (2008) Ghrelin, des-acyl ghrelin and obestatin: three pieces of the same puzzle. Peptides 29:1255-1270.
173. Soares J-B, Rocha-Sousa A, Castro-Chaves P, Henriques-Coelho T, and Leite-Moreira AF (2006) Inotropic and lusitropic effects of ghrelin and their modulation by the endocardial endothelium, NO, prostaglandins, GHS-R1a and KCa channels. Peptides 27:1616-1623.
174. Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, Hosoda H, and Kangawa K (2008) Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 294:H426-H432.
175. St-Pierre DH, Karelis AD, Coderre L, Malita F, Fontaine J, Mignault D, Brochu M, Bastard J-P, Cianflone K, and Doucet E, et al. (2007) Association of acylated and nonacylated ghrelin with insulin sensitivity in overweight and obese postmenopausal women. J Clin Endocrinol Metab 92:264-269.
176. Sun Q, Ma Y, Zhang L, Zhao Y-F, Zang W-J, and Chen C (2010) Effects of GH secretagogues on contractility and Ca2+ homeostasis of isolated adult rat ventricular myocytes. Endocrinology 151:4446-4454.
177. Sun Y, Wang P, Zheng H, and Smith RG (2004) Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 101:4679-4684.
178. Svensson J, Monson JP, Vetter T, Hansen TK, Savine R, Kann P, Bex M, Reincke M, Hagen C, and Beckers A, et al.; NN703 Clinical Research Group (2003) Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 58:572-580.
179. Takahashi K, Furukawa C, Takano A, Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, and Sone S, et al. (2006) The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 66:9408-9419.
180. Thielemans L, Peeters PJ, Jonckheere H, Luyten W, de Hoogt R, Coulie B, and Aerssens J (2007) The hepatocarcinoma cell line HepG2 does not express a GHS-R1a-type ghrelin receptor. J Recept Signal Transduct Res 27:309-322.
181. Thompson NM, Gill DAS, Davies R, Loveridge N, Houston PA, Robinson ICAF, and Wells T (2004) Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145:234-242.
182. Togliatto G, Trombetta A, Dentelli P, Baragli A, Rosso A, Granata R, Ghigo D, Pegoraro L, Ghigo E, and Brizzi MF (2010) Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes 59:1016-1025.
183. Togliatto G, Trombetta A, Dentelli P, Cotogni P, Rosso A, Tschöp MH, Granata R, Ghigo E, and Brizzi MF (2013) Unacylated ghrelin promotes skeletal muscle regeneration following hindlimb ischemia via SOD-2-mediated miR-221/222 expression. J Am Heart Assoc 2:e000376.
184. Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, Tschöp MH, and D'Alessio D (2010) Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 59:2145-2151.
185. Tong J, Davis HW, Summer S, Benoit SC, Haque A, Bidlingmaier M, Tschöp MH, and D'Alessio D (2014) Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans. Diabetes 63:2309-2319.
186. Toshinai K, Yamaguchi H, Sun Y, Smith RG, Yamanaka A, Sakurai T, Date Y, Mondal MS, Shimbara T, and Kawagoe T, et al. (2006) Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 147:2306-2314.
187. Tringali G, Greco MC, Lisi L, Pozzoli G, and Navarra P (2012) Cortistatin modulates the expression and release of corticotrophin releasing hormone in rat brain. Comparison with somatostatin and octreotide. Peptides 34:353-359.
188. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, and Heiman ML (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50:707-709.
189. Tsubota Y, Owada-Makabe K, Yukawa K, and Maeda M (2005) Hypotensive effect of des-acyl ghrelin at nucleus tractus solitarii of rat. Neuroreport 16:163-166.
190. Ueberberg B, Unger N, Saeger W, Mann K, and Petersenn S (2009) Expression of ghrelin and its receptor in human tissues. Horm Metab Res 41:814-821.
191. Valentin-Hansen L, Holst B, Frimurer TM, and Schwartz TW (2012) PheVI:09 (Phe6.44) as a sliding microswitch in seven-transmembrane (7TM) G proteincoupled receptor activation. J Biol Chem 287:43516-43526.
192. van der Lely AJ, Tschöp M, Heiman ML, and Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25: 426-457.
193. Venkova K, Mann W, Nelson R, and Greenwood-Van Meerveld B (2009) Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 329:1110-1116.
194. Vestergaard ET, Gormsen LC, Jessen N, Lund S, Hansen TK, Moller N, and Jorgensen JOL (2008) Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes 57: 3205-3210.
195. White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, Wei JY, Hoffman AR, Salvatori R, and Ettinger MP, et al.; Capromorelin Study Group (2009) Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 94:1198-1206.
196. Witherington J, Abberley L, Briggs MA, Collis K, Dean DK, Gaiba A, King NP, Kraus H, Shuker N, and Steadman JGA, et al. (2008) Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation. Bioorg Med Chem Lett 18:2203-2205.
197. Wortley KE, Anderson KD, Garcia K, Murray JD, Malinova L, Liu R, Moncrieffe M, Thabet K, Cox HJ, and Yancopoulos GD, et al. (2004) Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci USA 101:8227-8232.
198. Xu X-B, Cao J-M, Pang J-J, Xu R-K, Ni C, Zhu W-L, Asotra K, Chen M-C, and Chen C (2003) The positive inotropic and calcium-mobilizing effects of growth hormonereleasing peptides on rat heart. Endocrinology 144:5050-5057.
199. Xu X, Jhun BS, Ha CH, and Jin Z-G (2008) Molecular mechanisms of ghrelinmediated endothelial nitric oxide synthase activation. Endocrinology 149: 4183-4192.
200. Yeh AH, Jeffery PL, Duncan RP, Herington AC, and Chopin LK (2005) Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin Cancer Res 11: 8295-8303.
201. Yu AP, Pei XM, Sin TK, Yip SP, Yung BY, Chan LW, Wong CS, and Siu PM (2014) Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle. Acta Physiol (Oxf) 211:201-213.
202. Zhang G-G, Teng X, Liu Y, Cai Y, Zhou Y-B, Duan X-H, Song J-Q, Shi Y, Tang C-S, and Yin X-H, et al. (2009) Inhibition of endoplasm reticulum stress by ghrelin protects against ischemia/reperfusion injury in rat heart. Peptides 30:1109-1116.
203. Zhang Q, Huang WD, Lv XY, and Yang YM (2011) Ghrelin protects H9c2 cells from hydrogen peroxide-induced apoptosis through NF-kB and mitochondria-mediated signaling. Eur J Pharmacol 654:142-149.
204. Zhao H, Serby MD, and Liu B (2008) The prospects of antagonizing the growth hormone secretagogue receptor to treat obesity. Expert Opin Ther Patents 18: 989-998.
205. Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, Jones JE, Deysher AE, Waxman AR, and White RD, et al. (2005) Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115: 3564-3572.